Insider Trading February 10, 2026

Knowles SVP Sells $267,500 in Stock as Shares Continue Upward Move

Raymond Cabrera's February sales coincide with quarterly beats and an analyst reiteration amid elevated valuation signals

By Marcus Reed KN
Knowles SVP Sells $267,500 in Stock as Shares Continue Upward Move
KN

Raymond D. Cabrera, senior vice president and chief human resources officer at Knowles Corp (NYSE: KN), sold 10,000 shares on Feb. 9, 2026 for $26.75 per share, generating $267,500 in proceeds. The company has reported stronger-than-expected fourth-quarter results and received an analyst reiteration, while valuation metrics from InvestingPro flag the stock as trading above fair value despite robust financial health indicators.

Key Points

  • SVP and Chief HR Officer Raymond D. Cabrera sold 10,000 Knowles shares on Feb. 9, 2026 for $26.75 each, totaling $267,500.
  • Cabrera also had 2,588 shares withheld on Feb. 6, 2026 to cover taxes on a restricted stock vesting, valued at $26.98 per share and totaling $69,824; he now directly owns 102,019 shares.
  • Knowles beat Q4 2025 estimates with EPS of $0.36 and revenue of $162.0 million; Baird reiterated an Outperform rating with a $30.00 target, while InvestingPro flags the stock as overvalued despite a Piotroski Score of 9.

Insider transactions

Raymond D. Cabrera, Knowles Corp's senior vice president and chief human resources officer, reported the sale of 10,000 shares of common stock on February 9, 2026, at $26.75 per share, for total proceeds of $267,500. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.

The company's shares have continued to move higher since that sale, trading as high as $27.26 after the February 9 transaction and marking a 10.78% gain over the prior week.


Related disposition tied to tax withholding

In a separate report, the filings show Cabrera also disposed of 2,588 Knowles shares on February 6, 2026. Those shares were recorded at $26.98 apiece and reflect securities withheld to satisfy tax obligations connected to the vesting of a restricted stock grant, with a stated value of $69,824.

After these moves, Cabrera directly holds 102,019 shares of Knowles common stock.


Valuation and market context

InvestingPro data cited in the filing places Knowles at a market capitalization of $2.31 billion and notes the stock is trading close to its 52-week high of $27.55. The company is assigned a Piotroski Score of 9, indicating a strong financial health reading in that metric set.

Despite that favorable health score, InvestingPro's fair value model flags the stock as appearing overvalued relative to its estimate. Additional details and more than 17 ProTips are available within the Pro Research Report for subscribers seeking deeper valuation and growth analysis.


Quarterly performance and analyst view

Knowles reported fourth-quarter 2025 results that exceeded consensus expectations. The company posted earnings per share of $0.36 versus a forecast of $0.35, and revenue of $162.0 million compared with a projected $156.23 million.

In tandem with those results, Baird reiterated an Outperform rating on the shares and maintained a $30.00 price target. Baird highlighted Knowles' positioning for continued organic revenue growth and pointed to new design wins and what it described as a normalized channel inventory as contributors to potential revenue gains above historical levels.


Takeaway

The filings document a modest insider sale by a senior executive, while company fundamentals and analyst commentary show recent positive momentum in results and outlook. At the same time, third-party valuation tools indicate the stock is trading above fair value, underscoring a mixed signal set for investors evaluating Knowles shares.

Risks

  • Valuation concerns - InvestingPro indicates the stock appears overvalued compared with its fair value estimate, which could affect investor returns and market sentiment in the equities sector.
  • Proximity to 52-week high - The share price is trading near its 52-week high of $27.55, introducing potential price volatility for equity investors.
  • Limited disclosure on sale rationale - The filings describe the mechanics of the transactions but do not provide additional context on the executive's motivations, leaving uncertainty for market participants.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026